{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T12:46:11Z","timestamp":1777121171300,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81802561"],"award-info":[{"award-number":["No. 81802561"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of\u00a0Hunan Province","doi-asserted-by":"publisher","award":["No. 2019JJ50977"],"award-info":[{"award-number":["No. 2019JJ50977"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Funct Integr Genomics"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s10142-022-00870-8","type":"journal-article","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T23:02:46Z","timestamp":1654642966000},"page":"937-950","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Oncogenic GBX2 promotes the malignant behaviors of bladder cancer cells by binding to the ITGA5 promoter and activating its transcription"],"prefix":"10.1007","volume":"22","author":[{"given":"Yaoyao","family":"Xiong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohang","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Kudusi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiongbing","family":"Zu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minfeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8909-9008","authenticated-orcid":false,"given":"Wei","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,8]]},"reference":[{"issue":"3","key":"870_CR1","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.hoc.2021.02.004","volume":"35","author":"H Ahmadi","year":"2021","unstructured":"Ahmadi H, Duddalwar V, Daneshmand S (2021) Diagnosis and staging of bladder cancer. Hematol Oncol Clin North Am 35(3):531\u2013541","journal-title":"Hematol Oncol Clin North Am"},{"issue":"6","key":"870_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394\u2013424","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"870_CR3","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1007\/s00405-021-06636-5","volume":"278","author":"X Chen","year":"2021","unstructured":"Chen X, Cheng P, Hu C (2021) LncRNA FEZF1-AS1 accelerates the migration and invasion of laryngeal squamous cell carcinoma cells through miR-4497 targeting GBX2. Eur Arch Otorhinolaryngol 278(5):1523\u20131535","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"1","key":"870_CR4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/00005392-199707000-00017","volume":"158","author":"MS Cookson","year":"1997","unstructured":"Cookson MS et al (1997) The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 158(1):62\u201367","journal-title":"J Urol"},{"issue":"30","key":"870_CR5","doi-asserted-by":"publisher","first-page":"48547","DOI":"10.18632\/oncotarget.10423","volume":"7","author":"X Cui","year":"2016","unstructured":"Cui X et al (2016) miR-130b, an onco-miRNA in bladder cancer, is directly regulated by NF-kappaB and sustains NF-kappaB activation by decreasing Cylindromatosis expression. Oncotarget 7(30):48547\u201348561","journal-title":"Oncotarget"},{"issue":"3","key":"870_CR6","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/cncr.22031","volume":"107","author":"A Dash","year":"2006","unstructured":"Dash A et al (2006) Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 107(3):506\u2013513","journal-title":"Cancer"},{"issue":"22","key":"870_CR7","first-page":"5365","volume":"53","author":"B Davies","year":"1993","unstructured":"Davies B et al (1993) Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res 53(22):5365\u20135369","journal-title":"Cancer Res"},{"issue":"3","key":"870_CR8","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/nrc745","volume":"2","author":"M Egeblad","year":"2002","unstructured":"Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2(3):161\u2013174","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"870_CR9","first-page":"1391","volume":"58","author":"AC Gao","year":"1998","unstructured":"Gao AC, Lou W, Isaacs JT (1998) Down-regulation of homeobox gene GBX2 expression inhibits human prostate cancer clonogenic ability and tumorigenicity. Cancer Res 58(7):1391\u20131394","journal-title":"Cancer Res"},{"issue":"2","key":"870_CR10","first-page":"493","volume":"6","author":"AC Gao","year":"2000","unstructured":"Gao AC, Lou W, Isaacs JT (2000) Enhanced GBX2 expression stimulates growth of human prostate cancer cells via transcriptional up-regulation of the interleukin 6 gene. Clin Cancer Res 6(2):493\u2013497","journal-title":"Clin Cancer Res"},{"issue":"4","key":"870_CR11","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.3892\/or.2016.4985","volume":"36","author":"C Gong","year":"2016","unstructured":"Gong C et al (2016) miR-17 inhibits ovarian cancer cell peritoneal metastasis by targeting ITGA5 and ITGB1. Oncol Rep 36(4):2177\u20132183","journal-title":"Oncol Rep"},{"issue":"5","key":"870_CR12","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646\u2013674","journal-title":"Cell"},{"issue":"7472","key":"870_CR13","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature12751","volume":"502","author":"K Helin","year":"2013","unstructured":"Helin K, Dhanak D (2013) Chromatin proteins and modifications as drug targets. Nature 502(7472):480\u2013488","journal-title":"Nature"},{"issue":"3","key":"870_CR14","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.euo.2018.08.003","volume":"2","author":"R Jeyapala","year":"2019","unstructured":"Jeyapala R et al (2019) GBX2 methylation is a novel prognostic biomarker and improves prediction of biochemical recurrence among patients with prostate cancer negative for intraductal carcinoma and cribriform architecture. Eur Urol Oncol 2(3):231\u2013238","journal-title":"Eur Urol Oncol"},{"issue":"9","key":"870_CR15","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1158\/1078-0432.CCR-06-1187","volume":"13","author":"AK Kader","year":"2007","unstructured":"Kader AK et al (2007) Matrix metalloproteinase polymorphisms are associated with bladder cancer invasiveness. Clin Cancer Res 13(9):2614\u20132620","journal-title":"Clin Cancer Res"},{"issue":"5","key":"870_CR16","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nrc1877","volume":"6","author":"R Kalluri","year":"2006","unstructured":"Kalluri R, Zeisberg M (2006) Fibroblasts in cancer. Nat Rev Cancer 6(5):392\u2013401","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"870_CR17","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.cell.2013.02.014","volume":"152","author":"TI Lee","year":"2013","unstructured":"Lee TI, Young RA (2013) Transcriptional regulation and its misregulation in disease. Cell 152(6):1237\u20131251","journal-title":"Cell"},{"key":"870_CR18","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3389\/fonc.2013.00222","volume":"3","author":"UK Marelli","year":"2013","unstructured":"Marelli UK et al (2013) Tumor targeting via integrin ligands. Front Oncol 3:222","journal-title":"Front Oncol"},{"issue":"12","key":"870_CR19","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1016\/j.febslet.2010.04.002","volume":"584","author":"JH Martens","year":"2010","unstructured":"Martens JH, Stunnenberg HG (2010) The molecular signature of oncofusion proteins in acute myeloid leukemia. FEBS Lett 584(12):2662\u20132669","journal-title":"FEBS Lett"},{"issue":"16","key":"870_CR20","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1200\/JCO.2015.65.9797","volume":"34","author":"MI Milowsky","year":"2016","unstructured":"Milowsky MI et al (2016) Guideline on muscle-invasive and metastatic bladder cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J Clin Oncol 34(16):1945\u20131952","journal-title":"J Clin Oncol"},{"issue":"11","key":"870_CR21","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1111\/cas.13384","volume":"108","author":"M Miyake","year":"2017","unstructured":"Miyake M et al (2017) Diagnostic and prognostic role of urinary collagens in primary human bladder cancer. Cancer Sci 108(11):2221\u20132228","journal-title":"Cancer Sci"},{"issue":"5","key":"870_CR22","first-page":"969","volume":"45","author":"SMH Musavi Shenas","year":"2017","unstructured":"Musavi Shenas SMH et al (2017) SiRNA-mediated silencing of Snail-1 induces apoptosis and alters micro RNA expression in human urinary bladder cancer cell line. Artif Cells Nanomed. Biotechnol 45(5):969\u2013974","journal-title":"Biotechnol"},{"issue":"2","key":"870_CR23","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.eururo.2013.09.050","volume":"66","author":"G Ploussard","year":"2014","unstructured":"Ploussard G et al (2014) Conditional survival after radical cystectomy for bladder cancer: evidence for a patient changing risk profile over time. Eur Urol 66(2):361\u2013370","journal-title":"Eur Urol"},{"issue":"5","key":"870_CR24","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1158\/1078-0432.CCR-11-2271","volume":"18","author":"M Riester","year":"2012","unstructured":"Riester M et al (2012) Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. Clin Cancer Res 18(5):1323\u20131333","journal-title":"Clin Cancer Res"},{"issue":"12","key":"870_CR25","first-page":"2786","volume":"7","author":"T Song","year":"2015","unstructured":"Song T et al (2015) Decrement of miR-199a-5p contributes to the tumorigenesis of bladder urothelial carcinoma by regulating MLK3\/NF-kappaB pathway. Am J Transl Res 7(12):2786\u20132794","journal-title":"Am J Transl Res"},{"issue":"5","key":"870_CR26","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/nrurol.2011.44","volume":"8","author":"T Szarvas","year":"2011","unstructured":"Szarvas T et al (2011) Matrix metalloproteinases and their clinical relevance in urinary bladder cancer. Nat Rev Urol 8(5):241\u2013254","journal-title":"Nat Rev Urol"},{"issue":"2","key":"870_CR27","doi-asserted-by":"publisher","first-page":"e3147","DOI":"10.1002\/jgm.3147","volume":"22","author":"Y Wang","year":"2020","unstructured":"Wang Y et al (2020) GBX2, as a tumor promoter in lung adenocarcinoma, enhances cells viability, invasion and migration by regulating the AKT\/ERK signaling pathway. J Gene Med 22(2):e3147","journal-title":"J Gene Med"},{"key":"870_CR28","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.canlet.2018.06.037","volume":"433","author":"Y Xiao","year":"2018","unstructured":"Xiao Y et al (2018) Integrin alpha5 down-regulation by miR-205 suppresses triple negative breast cancer stemness and metastasis by inhibiting the Src\/Vav2\/Rac1 pathway. Cancer Lett 433:199\u2013209","journal-title":"Cancer Lett"},{"key":"870_CR29","doi-asserted-by":"publisher","first-page":"e2088","DOI":"10.1038\/cddis.2015.274","volume":"7","author":"X Xu","year":"2016","unstructured":"Xu X et al (2016) c-Met and CREB1 are involved in miR-433-mediated inhibition of the epithelial-mesenchymal transition in bladder cancer by regulating Akt\/GSK-3beta\/Snail signaling. Cell Death Dis 7:e2088","journal-title":"Cell Death Dis"}],"container-title":["Functional & Integrative Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10142-022-00870-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10142-022-00870-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10142-022-00870-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T12:52:26Z","timestamp":1665406346000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10142-022-00870-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,8]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["870"],"URL":"https:\/\/doi.org\/10.1007\/s10142-022-00870-8","relation":{},"ISSN":["1438-793X","1438-7948"],"issn-type":[{"value":"1438-793X","type":"print"},{"value":"1438-7948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,8]]},"assertion":[{"value":"9 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}